Our top pick for
Translate Bio Inc is a biotechnology business based in the US. Translate Bio shares (TBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Translate Bio employs 122 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$37.36|
|52-week range||$12.51 - $37.99|
|50-day moving average||$37.53|
|200-day moving average||$25.48|
|Wall St. target price||$32.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.53|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||N/A|
|1 month (2021-09-20)||N/A|
|3 months (2021-07-23)||24.53%|
|6 months (2021-04-23)||72.88%|
|1 year (2020-10-23)||166.29%|
|2 years (2019-10-23)||315.57%|
|3 years (2018-10-23)||584.25%|
|5 years (2016-10-20)||N/A|
Valuing Translate Bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Translate Bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Translate Bio's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 71x. In other words, Translate Bio shares trade at around 71x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Translate Bio's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $45.1 million.
The EBITDA is a measure of a Translate Bio's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$225.1 million|
|Operating margin TTM||18.52%|
|Gross profit TTM||$79.3 million|
|Return on assets TTM||3.83%|
|Return on equity TTM||11.83%|
|Market capitalisation||$2.8 billion|
TTM: trailing 12 months
There are currently 4.3 million Translate Bio shares held short by investors – that's known as Translate Bio's "short interest". This figure is 43.2% up from 3.0 million last month.
There are a few different ways that this level of interest in shorting Translate Bio shares can be evaluated.
Translate Bio's "short interest ratio" (SIR) is the quantity of Translate Bio shares currently shorted divided by the average quantity of Translate Bio shares traded daily (recently around 5.8 million). Translate Bio's SIR currently stands at 0.74. In other words for every 100,000 Translate Bio shares traded daily on the market, roughly 740 shares are currently held short.
However Translate Bio's short interest can also be evaluated against the total number of Translate Bio shares, or, against the total number of tradable Translate Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Translate Bio's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Translate Bio shares in existence, roughly 60 shares are currently held short) or 0.0882% of the tradable shares (for every 100,000 tradable Translate Bio shares, roughly 88 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Translate Bio.
Find out more about how you can short Translate Bio stock.
We're not expecting Translate Bio to pay a dividend over the next 12 months.
Over the last 12 months, Translate Bio's shares have ranged in value from as little as $12.51 up to $37.985. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Translate Bio's is 0.9704. This would suggest that Translate Bio's shares are less volatile than average (for this exchange).
Translate Bio, Inc. , a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.